Blood Transcriptome Profiling in Myasthenia Gravis Patients to Assess Disease Activity: A Pilot RNA-seq Study.
- Author:
Kee Hong PARK
1
;
Junghee JUNG
;
Jung Hee LEE
;
Yoon Ho HONG
Author Information
- Publication Type:Original Article
- Keywords: Transcriptome; RNA sequencing; myasthenia gravis; cell migration; apoptosis
- MeSH: Apoptosis; Autoimmune Diseases; Cell Death; Cell Movement; Gene Expression Profiling*; Humans; Myasthenia Gravis*; Sequence Analysis, RNA; Transcriptome*
- From:Experimental Neurobiology 2016;25(1):40-47
- CountryRepublic of Korea
- Language:English
- Abstract: Myasthenia gravis (MG) is an antibody-mediated autoimmune disease characterized by exertional weakness. There is no biomarker to reflect disease activity and guide treatment decision. Here, we reported a pilot blood transcriptome study using RNA sequencing (RNA-seq) that identified differences of 5 samples in active status and 5 in remission from 8 different patients and 2 patients provided samples for both active and remission phase. We found a total of 28 differentially expressed genes (DEGs) possibly related to disease activity (23 up-regulated and 5 down-regulated). The DEGs were enriched for the cell motion and cell migration processes in which included were ICAM1, CCL3, S100P and GAB2. The apoptosis and cell death pathway was also significantly enriched, which includes NFKBIA, ZC3H12A, TNFAIP3, and PPP1R15A. Our result suggests that transcript abundance profiles of the genes involved in cell trafficking and apoptosis may be a molecular signature of the disease activity in MG patients.
